Patents by Inventor Klaus Fuchs

Klaus Fuchs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100249158
    Abstract: The present invention relates to substituted amino-quinazolinones of general formula (I) wherein the groups R1 to R14 and A, are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.
    Type: Application
    Filed: July 3, 2008
    Publication date: September 30, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Klaus Fuchs, Niklas Heine, Christian Eickmeier, Sandra Handschuh, Cornelia Dorner-Ciossek, Stefan Hoerer
  • Publication number: 20100204160
    Abstract: The present invention relates to substituted 1,2-ethylenediamines of general formula (I) wherein the groups R1 to R15, A, B, L, i as well as X1-X4 are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.
    Type: Application
    Filed: April 13, 2010
    Publication date: August 12, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Christian EICKMEIER, Stefan PETERS, Klaus FUCHS, Niklas HEINE, Sandra HANDSCHUH, Cornelia DORNER-CIOSSEK, Klaus KLINDER, Marcus KOSTKA
  • Publication number: 20100168070
    Abstract: The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the radicals R1-R13, A, B, L and i are as defined in the description and in the claims. The invention also relates to the use thereof for treating Alzheimer's disease (AD) and similar diseases.
    Type: Application
    Filed: August 8, 2006
    Publication date: July 1, 2010
    Inventors: Niklas Heine, Klaus Fuchs, Christian Eickmeier, Stefan Peters, Cornelia Dorner-Ciossek, Sandra Handschuh, Herbert Nar, Klaus Klinder
  • Publication number: 20100144681
    Abstract: The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the radicals R1-R13, A, B, L and i are as defined in the description and the claims. The invention also relates to the use thereof for treating Alzheimer's disease (AD) and similar diseases.
    Type: Application
    Filed: August 8, 2006
    Publication date: June 10, 2010
    Inventors: Klaus Fuchs, Christian Eickmeier, Niklas Heine, Stefan Peters, Cornelia Dorner-Ciossek, Sandra Handschuh, Herbert Nar, Klaus Klinder
  • Patent number: 7713961
    Abstract: The present invention relates to substituted 1,2-ethylenediamines of general formula (I) wherein the groups R1 to R15, A, B, L, i as well as X1—X4 are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.
    Type: Grant
    Filed: March 30, 2006
    Date of Patent: May 11, 2010
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christian Eickmeier, Stefan Peters, Klaus Fuchs, Niklas Heine, Sandra Handschuh, Cornelia Dorner-Ciossek, Klaus Klinder, Marcus Kostka
  • Publication number: 20090325940
    Abstract: The present invention relates to substituted 1,2-ethylenediamines of general formula (I) wherein the groups R1 to R15, A, B, L, i as well as X1-X4 are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.
    Type: Application
    Filed: July 29, 2009
    Publication date: December 31, 2009
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Christian Eickmeier, Stefan Peters, Klaus Fuchs, Niklas Heine, Sandra Handschuh, Cornelia Dorner-Ciossek, Klaus Klinder, Marcus Kostka
  • Publication number: 20090042867
    Abstract: The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the radicals R1 to R13, A, B, L, and i are defined as indicated in the description and the claims, as well as the use thereof for treating Alzheimer's disease (AD) and similar diseases.
    Type: Application
    Filed: August 8, 2006
    Publication date: February 12, 2009
    Inventors: Klaus Fuchs, Christian Eickmeier, Niklas Heine, Stefan Peters, Cornelia Dorner-Ciossek, Sandra Handschuh, Herbert Nar, Klaus Klinder
  • Publication number: 20080293680
    Abstract: The invention relates to a compound of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and R8 are defined as in the specification and claims and to its use for treating or preventing Alzheimer's disease and other similar diseases.
    Type: Application
    Filed: August 1, 2006
    Publication date: November 27, 2008
    Inventors: Stefan Peters, Christian Eickmeier, Klaus Fuchs, Werner Stransky, Cornelia Dorner-Ciossek, Marcus Kostka, Sandra Handschuh, Herbert Nar, Klaus Bornemann, Klaus Klinder, Margit Bauer
  • Patent number: 7238774
    Abstract: The invention relates to a compound of the formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and R8 are defined as in the specification and claims and to its use for treating or preventing Alzheimer's disease and other similar diseases.
    Type: Grant
    Filed: November 7, 2005
    Date of Patent: July 3, 2007
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Stefan Peters, Klaus Fuchs, Christian Eickmeier, Werner Stransky, Cornelia Dorner-Ciossek, Sandra Handschuh, Herbert Nar, Klaus Klinder, Marcus Kostka
  • Patent number: 7166599
    Abstract: The present invention relates to trisubstituted pyrimidines of formula wherein Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses in which ?-amyloid modulators have a therapeutic benefit, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
    Type: Grant
    Filed: December 9, 2004
    Date of Patent: January 23, 2007
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Klaus Bornemann, Hans Briem, Cornelia Dorner-Ciossek, Katja Fechteler, Klaus Fuchs, Frank Himmelsbach, Klaus Klinder, Markus Kostka
  • Publication number: 20060223759
    Abstract: The present invention relates to substituted 1,2-ethylenediamines of general formula (I) wherein the groups R1 to R15, A, B, L, i as well as X1-X4 are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.
    Type: Application
    Filed: March 30, 2006
    Publication date: October 5, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Christian Eickmeier, Stefan Peters, Klaus Fuchs, Niklas Heine, Sandra Handschuh, Cornelia Dorner-Ciossek, Klaus Klinder, Marcus Kostka
  • Publication number: 20060160747
    Abstract: The invention relates to a compound of the formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined as in the specification and claims and to its use for treating or preventing Alzheimer's disease and other similar diseases.
    Type: Application
    Filed: November 7, 2005
    Publication date: July 20, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Stefan Peters, Klaus Fuchs, Christian Eickmeier, Werner Stransky, Cornelia Dorner-Ciossek, Sandra Handschuh, Herbert Nar, Klaus Klinder, Marcus Kostka
  • Publication number: 20060100158
    Abstract: The invention relates to a compound of the formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and R8 are defined as in the specification and claims and to its use for treating or preventing Alzheimer's disease and other similar diseases.
    Type: Application
    Filed: November 7, 2005
    Publication date: May 11, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Stefan Peters, Klaus Fuchs, Christian Eickmeier, Werner Stransky, Cornelia Dorner-Ciossek, Sandra Handschuh, Herbert Nar, Klaus Klinder, Marcus Kostka
  • Publication number: 20060025345
    Abstract: The invention relates to a compound of the formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, A, B, and Y are defined as in the specification and claims and to its use for treating or preventing Alzheimer's disease and other similar diseases.
    Type: Application
    Filed: May 20, 2005
    Publication date: February 2, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Stefan Peters, Christian Eickmeier, Klaus Fuchs, Werner Stransky, Cornelia Dorner-Ciossek, Marcus Kostka, Sandra Handschuh, Margit Bauer, Herbert Nar, Klaus Bornemann, Klaus Klinder, Joerg Rademann, Steffen Weik
  • Publication number: 20050090449
    Abstract: The invention relates to a compound of the formula wherein R1, R2, X, Y, n, t and m are defined as in the specification and claims and to its use for treating or preventing Alzheimer's disease and other similar diseases.
    Type: Application
    Filed: May 6, 2004
    Publication date: April 28, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Klaus Fuchs, Stefan Peters, Comelia Dorner-Ciossek, Marcus Kostka, Sandra Handschuh, Christian Haass
  • Publication number: 20050090486
    Abstract: The present invention relates to trisubstituted pyrimidines of formula wherein Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses in which ?-amyloid modulators have a therapeutic benefit, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
    Type: Application
    Filed: December 9, 2004
    Publication date: April 28, 2005
    Applicant: Boehringer Ingelheim Pharma KG
    Inventors: Klaus Bornemann, Hans Briem, Cornelia Dorner-Ciossek, Katja Fechteler, Klaus Fuchs, Frank Himmelsbach, Klaus Klinder, Markus Kostka
  • Patent number: 6770636
    Abstract: Compounds of formula 1, wherein: R1 is hydrogen, hydroxy, CF3, NO2, CN, halogen, C1-C8-alkyl, or C1-C8-alkoxy; R2, R3, and R4 independently of one another are hydrogen, C1-C8-alkyl, hydroxy, NO2, CN, C1-C8-alkoxyl, CF3, or halogen; R5 and R6 independently of one another are hydrogen or a group consisting of C1-C8-alkyl, C2-C8-alkenyl, C3-C8-alkynyl, C3-C8-cycloalkyl, C3-C8-cycloalkyl-C1-C6-alkylene, C5-C8-cycloalkenyl, C5-C8-cycloalkenyl-C1-C6-alkylene, C6-C10-aryl, and C6-C10-aryl-C1-C6-alkylene, each optionally substituted by a group consisting of C1-C6-alkyl, C2-C6-alkenyl, halogen, C1-C6-alkyloxy, —NH2, —NH(C1-C4-alkyl), —N(C1-C4-alkyl)2, hydroxy, ═O, —COOH, —CO—OC1-C4-alkyl, —CONH2, —CONH(C1-C4-alkyl), —CON(C1-C4-alkyl)2, and CF3, or R5 and R6 together with the nitrogen atom are a saturated or unsaturated 5-, 6-, 7-, or 8-membered heterocyclic group optionally containing one or two further heteroatoms consisting of sulfur, o
    Type: Grant
    Filed: July 24, 2001
    Date of Patent: August 3, 2004
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Klaus Fuchs, Werner Stransky, Matthias Grauert, Adrian Carter, Wolfram Gaida, Thomas Weiser, Helmut Ensinger
  • Publication number: 20030134838
    Abstract: The present invention relates to trisubstituted pyrimidines of formula 1
    Type: Application
    Filed: October 16, 2002
    Publication date: July 17, 2003
    Applicant: Boehringer Ingelheim Pharma KG
    Inventors: Klaus Bornemann, Hans Briem, Cornelia Dorner-Clossek, Katja Fechteler, Klaus Fuchs, Frank Himmelsbach, Klaus Klinder, Markus Kostka
  • Patent number: 6514969
    Abstract: Compounds of general formula (I) wherein: A is —CH2—, —CH2—CH2—, —CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—, —CH2—CO—, —CH2—CH2—CO—, or —CH═CH—CO—; Het is piperidinyl, piperazinyl, or dihydrobenzimidazolonyl; R1 is hydrogen or halogen; R2 is hydrogen, C1-C4-alkyl, CF3, or a phenyl group optionally substituted by halogen, C1-C4-alkyl, or C1-C4-alkyloxy; and R3 is hydrogen, C1-C4-alkyl, HO—C1-C4-alkyl, or C2-C4-alkenyl; or a group selected from phenyl, benzyl, and phenylethyl, each optionally substituted by halogen, CF3, C1-C4-alkyl, or C1-C4-alkyloxy; or a heterocycle selected from among morpholine, piperidine, piperazine, and dihydrobenzimidazolone, the heterocycle either linked directly or via a C1-C4-alkylene bridge, or an optical isomer, enantiomer, tautomer, free base, or pharmacologically acceptable acid addition salt thereof; methods of
    Type: Grant
    Filed: July 24, 2001
    Date of Patent: February 4, 2003
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Hans Briem, Klaus Mendla, Helmut Michael Romig, Katja Fechteler, Klaus Fuchs
  • Publication number: 20030022251
    Abstract: According to the screening method of the invention substances capable of modulating &ggr;-secretase activity are identified by incubating a source and a substrate of &ggr;-secretase activity with a test substance and detecting a C-terminal fragment released from said substrate.
    Type: Application
    Filed: June 26, 2002
    Publication date: January 30, 2003
    Applicant: Boehringer Ingelheim Pharma KG
    Inventors: Klaus Fuchs, Cornelia Dorner-Ciossek, Marcus Kostka, Christian Haass, Harald Steiner